Every year, our scientists and patient advisory group identify the studies and topics creating the most impact for people living with arthritis.
Uncover Our Focus for 2026Ongoing and completed studies across our full research portfolio, from prevention and treatment to care and health systems.
Explore Our ResearchMeet the scientists, clinicians, trainees, and patient advisory board members, driving discoveries
Meet Our TeamArthritis Research Canada's scientists and trainees regularly present new findings that advance arthritis prevention, treatment, and care.
Browse Conference AbstractsPeople living with arthritis guide our research priorities, shape study design, and ensure our work reflects real life.
Support Arthritis Research Canada with your time and skills. Whether you want to help at an event or host your own, there is a place for you here.
Living with arthritis? Explore open studies looking for participants and help shape the future of arthritis care.
Your experience with arthritis matters. Sharing it helps others feel less alone and brings the human reality of arthritis into everything we do.
Execution of Research
SpA (short for ‘spondyloarthritis’) is a type of inflammatory arthritis that affects the back, hips, and often other parts of the body. Biologic drugs (also called ‘anti-TNF’ therapies) are used to help stop inflammation from SpA. Doctors have made recommendations about who should use biologic drugs, as they are expensive and may have side effects. The DESIR cohort is a group of 708 French SpA patients who are responding to follow-up questions every six months about their costs and health. This study used information from DESIR to look at the effect of following doctors’ recommendations about who should use biologic drugs. To make sure this effect was understood in context, the study also looked at the effect of following other recommendations, such as using physiotherapy. Researchers looked at effects on patients’ costs as well as health.
Because information in the DESIR cohort is collected only every six months, researchers found that it was difficult to know for sure which patients would be recommended a biologic. Since this could affect the study findings, researchers decided to look at the information two different ways. The first way, the study showed that there were no differences in costs or in health between patients who received a biologic when recommended and those who did not. The second way, the study showed that patients who received a biologic when recommended had better health than those who did not, as well as reductions in certain types of costs. The study was important because it showed that researchers will need more information in order to know which SpA patients are being recommended a biologic. Future studies will be needed to know for sure how following recommendations about biologics affects patients’ costs and health.
Involvement
This study was led by a student researcher as part of a PhD thesis. A total of 7 researchers participated in the study.
Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis AH. Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. J Rheumatol. 2017 Oct;44(10):1436-1444.